Trevi Therapeutics, Inc. - Common Stock (TRVI)

CUSIP: 89532M101

Q2 2020 13F Holders as of 30 Jun 2020

Type / Class
Equity / Common Stock
Shares outstanding
128,120,714
Total 13F shares
13,374,829
Share change
-589,791
Total reported value
$88,003,000
Price per share
$6.58
Number of holders
12
Value change
-$1,315,702
Number of buys
6
Number of sells
10

Sponsored

Quarterly Holders Quick Answers

What is CUSIP 89532M101?
CUSIP 89532M101 identifies TRVI - Trevi Therapeutics, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of TRVI - Trevi Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
TPG Group Holdings (SBS) Advisors, Inc.
13F
Company
4.9%
6,324,319
 $20,807,000 — 31 Mar 2020
13F
NEA Management Company, LLC
13F
Company
3.5%
4,441,360
 $14,612,000 — 31 Mar 2020
13F
Omega Fund Management, LLC
13F
Company
0.99%
1,263,408
 $4,157,000 — 31 Mar 2020
13F
FMR LLC
13F
Company
0.62%
792,700
 $2,608,000 — 31 Mar 2020
13F
FRANKLIN RESOURCES INC
13F
Company
0.46%
587,347
 $1,932,000 — 31 Mar 2020
13F
VANGUARD GROUP INC
13F
Company
0.12%
150,432
 $495,000 — 31 Mar 2020
13F
DRIEHAUS CAPITAL MANAGEMENT LLC
13F
Company
0.09%
117,371
 $386,000 — 31 Mar 2020
13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC
13F
Company
0.06%
75,000
 $247,000 — 31 Mar 2020
13F
BANCO BILBAO VIZCAYA ARGENTARIA, S.A.
13F
Company
0.05%
70,000
 $230,000 — 31 Mar 2020
13F
Schonfeld Strategic Advisors LLC
13F
Company
0.05%
59,029
 $194,000 — 31 Mar 2020
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.03%
41,913
 $137,000 — 31 Mar 2020
13F
NORTHERN TRUST CORP
13F
Company
0.01%
16,480
 $54,000 — 31 Mar 2020
13F
STIFEL FINANCIAL CORP
13F
Company
0.01%
13,845
 $46,000 — 31 Mar 2020
13F
BlackRock Finance, Inc.
13F
Company
0.01%
9,072
 $30,000 — 31 Mar 2020
13F
FIFTH THIRD BANCORP
13F
Company
0%
1,000
 $3,000 — 31 Mar 2020
13F
VICTORY CAPITAL MANAGEMENT INC
13F
Company
0%
803
 $3,000 — 31 Mar 2020
13F
UBS Group AG
13F
Company
0%
541
 $2,000 — 31 Mar 2020
13F
PANAGORA ASSET MANAGEMENT INC
13F
Company
0%
406
 $1,000 — 31 Mar 2020
13F

Institutional Holders of Trevi Therapeutics, Inc. - Common Stock (TRVI) as of Q2 2020

As of 30 Jun 2020, Trevi Therapeutics, Inc. - Common Stock (TRVI) was held by 12 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 13,374,829 shares. The largest 10 holders included NEA Management Company, LLC, TPG Group Holdings (SBS) Advisors, Inc., Omega Fund Management, LLC, FMR LLC, VANGUARD GROUP INC, BRIDGEWAY CAPITAL MANAGEMENT INC, BANCO BILBAO VIZCAYA ARGENTARIA, S.A., GEODE CAPITAL MANAGEMENT, LLC, CANADA PENSION PLAN INVESTMENT BOARD, and BlackRock Inc.. This page lists 12 institutional shareholders reporting positions in this security for the Q2 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2020 vs Q1 2020 Across Filers

Q1 2020 holders
17
Q2 2020 holders
12
Holder diff
-5
Investor Q1 2020 Shares Q2 2020 Shares Share Diff Share Chg % Q1 2020 Value $ Q2 2020 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sponsored